Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.
Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...
Hungarys National Centre for Public Health and Pharmacy (NNGYK) is purchasing COVID-19 vaccines for adults and children from ...
The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine By India Edwards HealthDay Reporter TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS ...
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...
HealthDay News — The US Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.